Non-small Cell Lung Cancer
Conditions
Brief summary
The purpose of this study is to explore the safety and efficacy of herombopag olamine tablets for thrombocytopenia induced by chemotherapy combined with immunotherapy in non-small cell lung cancer
Detailed description
To observe and evaluate the safety and efficacy of the TPO receptor agonist herombopag for the secondary prevention of thrombocytopenia caused by chemotherapy combined with immunotherapy in non-small cell lung cancer.
Interventions
The first day of chemotherapy was d1, and the drug was started from d-5, 5 days before chemotherapy, with oral herombopag 5 mg/day for a maximum of 14 days. After chemotherapy, when the thrombocytopenia rises to ≥200×109/L, drug discontinuation can be considered
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Henan Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The patients signed the informed consent and voluntarily joined the study; 2. Age 18-75 years old, male or female; 3. Patients with stage IIIb-IV non-small cell lung cancer diagnosed by histopathology or cytology, who have received and will continue to receive carboplatin-based chemotherapy combined with pemetrexed or nab-paclitaxel, combined with immune checkpoint inhibitors ( ICIs) treatment; 4. The investigator determined that the patient could receive hetrombopag administration; 5. Thrombocytopenia of grade 2 or above occurred in the last chemotherapy cycle, defined as platelet count (PLT) ≤ 75×109/L; 6. The values of laboratory tests performed for screening shall meet the following criteria: 1\) Blood routine examination: a) Hemoglobin (HB) ≥ 90 g/L; b) Absolute neutrophil count (ANC) ≥ 1.5×109/L; c) Platelet count (PLT) ≥ 80×109/L; 2) Biochemical tests: a) AST and ALT ≤ 3 times ULN (if there is tumor liver metastasis, ≤ 5 times ULN); b) TBiL ≤ 2 times ULN; c) Cr ≤ 2 times ULN, or creatinine clearance (CrCL) ≥60 mL/min (Cockcroft-Gault formula); 7. Life expectancy at screening ≥12 weeks; 8. ECOG: 0-1; 9. The main organ functions are normal, and there are no serious complications;
Exclusion criteria
1. pregnant or breastfeeding women; 2. Inability to understand the research nature of the research or to obtain informed consent; 3. The investigator judges other circumstances that are not suitable for inclusion in the study; 4. Thrombocytopenia caused by other causes other than those caused by chemotherapy or immunotherapy (such as chronic liver disease, sepsis, disseminated intravascular coagulation, immune thrombocytopenia, etc.); 5. Have unstable angina pectoris, congestive heart failure, uncontrolled hypertension, uncontrolled arrhythmia or recent (within 1 year of screening) history of myocardial infarction; 6. Those with a history of blood disease or tumor bone marrow infiltration; 7. Those who received concurrent radiotherapy and those who received pelvic radiotherapy in the past; 8. Arterial or venous thrombotic events within the past 6 months; 9. There are currently uncontrollable infections.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the response rate of hetrombopag | Follow-up to 28 days after the last use of herombopag | response if all of the following criteria are met: 1. No need for platelet transfusion 2. No need to reduce chemotherapy drug dose due to thrombocytopenia 3. No need to delay chemotherapy due to thrombocytopenia) Note: chemotherapy drug dose reduction It was defined as reducing the dose of the original chemotherapy drug by ≥20%, and chemotherapy delay was defined as delaying chemotherapy by \>7 days. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The lowest platelet value after chemotherapy | Follow-up to 28 days after the last use of herombopag | The lowest platelet value after chemotherapy |
| Platelet recovery to the highest value after chemotherapy; | Follow-up to 28 days after the last use of herombopag | Platelet recovery to the highest value after chemotherapy; |
| Incidence of adverse events | Follow-up to 28 days after the last use of herombopag | Incidence of adverse events |
| The duration of platelets ≤50×109/L; | Follow-up to 28 days after the last use of herombopag | The duration of platelets ≤50×109/L; |
| The time for platelets to recover to more than 100×109/L; | Follow-up to 28 days after the last use of herombopag | The time for platelets to recover to more than 100×109/L; |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes of platelet value in each visit cycle | Follow-up to 28 days after the last use of herombopag | Changes of platelet value in each visit cycle |
Contacts
Primary Contactqiming wang
Backup Contactzhen he
Outcome results
None listed